Quick Answer
BioCorRx Inc. reported Diluted EPS of $0.19 per share (loss) for fiscal year 2025.
BioCorRx Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.19 | +61.2% |
| 2024 | -$0.49 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.11 | +21.4% | -57.1% |
| June 30, 2025 | -$0.07 | +46.2% | +50.0% |
| September 30, 2024 | -$0.14 | — | -7.7% |
| June 30, 2024 | -$0.13 | — | — |
| June 30, 2018 | $0.00 | -100.0% | -100.0% |
| June 30, 2017 | $0.02 | +300.0% | +300.0% |
| June 30, 2016 | -$0.01 | +50.0% | +50.0% |
| June 30, 2015 | -$0.02 | — | — |
- BioCorRx Inc. showed an increase of +61.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2024–2025 period, BioCorRx Inc.’s diluted eps has grown by 61.2% (from $0.49 per share (loss) to $0.19 per share (loss)).
- The most recent figure is from BioCorRx Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: